Form 4: Minerva Neurosciences Executive Granted Stock Options

Frederick W. Ahlholm, SVP, CFO and Secretary of Minerva Neurosciences, Inc., was granted 47,500 stock options on December 5, 2024.

Summary

• Frederick W. Ahlholm, the SVP, CFO and Secretary of Minerva Neurosciences, Inc., received 47,500 employee stock options on December 5, 2024.
• The exercise price of these options is $2.12 per share.
• The options vest 25% on December 5, 2025, and then in equal quarterly installments over the following three years.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document is a routine filing related to executive compensation, which is generally viewed neutrally to slightly positive as it aligns management with shareholder interests.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 25% after one year and then quarterly over three years is a typical vesting schedule for stock options.
• The exercise price of $2.12 is not directly comparable without knowing the current market price of the stock.

Stakeholder Impact

• The stock option grant may have a slightly positive impact on shareholder sentiment as it aligns executive interests with company performance.

Key Dates

Keywords

stock options, executive compensation, insider trading, Minerva Neurosciences, NERV, Frederick W. Ahlholm